Zexipag 400mcg Tablet contains Selexipag, a selective prostacyclin receptor (IP receptor) agonist indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce the risk of hospitalization. Selexipag acts by targeting the prostacyclin pathway, leading to vasodilation of pulmonary arteries and inhibition of smooth muscle cell proliferation, thereby improving exercise capacity and hemodynamics in patients with PAH. The 400mcg dosage is typically initiated and titrated based on individual patient tolerance to optimize therapeutic outcomes while minimizing adverse effects. Clinical studies have demonstrated that Selexipag effectively reduces morbidity and mortality associated with PAH when used as part of a comprehensive management plan. Common side effects may include headache, jaw pain, nausea, diarrhea, and flushing, which are generally manageable with dose adjustments. Zexipag should be administered under the supervision of a healthcare professional experienced in PAH management, with regular monitoring of clinical response and tolerability. It is contraindicated in patients with hypersensitivity to Selexipag or its excipients. Caution is advised in patients with hepatic impairment or concomitant use of strong CYP2C8 inhibitors. Adherence to prescribed dosing and follow-up is essential to achieve optimal therapeutic benefit.